An AbbVie-sponsored symposium at ESMO Asia 2025 addressed the critical need for new strategies to define and treat platinum resistance in advanced ovarian cancer. Experts highlighted that platinum-resistant advanced ovarian cancer has a poor prognosis and current treatment options are limited and often accompanied by significant side effects, affecting patients' quality of life. The discussion emphasized exploring novel approaches, including Antibody Drug Conjugates (ADCs), to improve efficacy, tolerability, and patient outcomes in this challenging disease.

艾伯维

<p>在 2025 年 ESMO 亚洲大会上，由艾伯维赞助的研讨会讨论了在晚期卵巢癌中定义和治疗铂耐药的迫切需求。专家们强调，铂耐药的晚期卵巢癌预后不良，当前的治疗选择有限，且常伴有显著的副作用，影响患者的生活质量。讨论强调了探索新方法的重要性，包括抗体药物偶联物（ADCs），以提高在这一具有挑战性的疾病中的疗效、耐受性和患者结果</p>

艾伯维赞助的 2025 年 ESMO 亚洲研讨会突出了铂耐药晚期卵巢癌的紧迫医疗需求